Statins downregulate k6a promoter activity: A possible therapeutic avenue for pachyonychia congenita

Journal of Investigative Dermatology

Volumn 131, Issue 5, 2011, Pages 1045-1052

  Zhao, Yiwei ^a   Gartner, Ulrike ^a   Smith, Frances J D ^a   McLean, W H Irwin ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYL GLUTARYL COENZYME A REDUCTASE; CHOLESTEROL; COMPACTIN; CYTOKERATIN 6; GAMMA INTERFERON; GERANYL ACETATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; ISOPRENOID; JANUS KINASE; MEVALONIC ACID; OXIDOREDUCTASE; SIMVASTATIN; STAT1 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CHOLESTEROL METABOLISM; CLINICAL TRIAL (TOPIC); CONGENITAL PACHYONYCHIA; DOWN REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 79954882368     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2011.41     Document Type: Article

References (46)

1. Abeles AM, Pillinger MH (2006) Statins as antiinflammatory and immuno-modulatory agents: a future in rheumatologic therapy? Arthritis Rheum 54:393-407 (Pubitemid 43228614)
2. Bernerd F, Magnaldo T, Freedberg IM et al. (1993) Expression of the carcinoma-associated keratin K6 and the role of AP-1 proto-oncoproteins. Gene Expr 3:187-99
3. Boukamp P, Petrussevska RT, Breitkreutz D et al. (1988) Normal keratiniza-tion in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 106:761-71 (Pubitemid 18089976)
4. Bowden PE, HaleyJL, Kansky A et al. (1995) Mutation of a type II keratin gene (K6a) in pachyonychia congenita. Nat Genet 10:363-5
5. Brown MS, Faust JR, Goldstein JL et al. (1978) Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase. J Biol Chem 253:1121-8 (Pubitemid 8288831)
6. Contursi C, Wang IM, Gabriele L et al. (2000) IFN consensus sequence binding protein potentiates STAT1-dependent activation of IFNgamma-responsive promoters in macrophages. Proc Natl Acad Sci USA 97:91-6 (Pubitemid 30055789)
7. de The H, Vivanco-Ruiz MM, Tiollais P et al. (1990) Identification of a retinoic acid responsive element in the retinoic acid receptor beta gene. Nature 343:177-80
8. Decker T, Kovarik P, Meinke A (1997) GAS elements: a few nucleotides with a major impact on cytokine-induced gene expression. J Interferon Cytokine Res 17:121-34 (Pubitemid 27148701)
9. Dickson M, Gagnon JP (2004) Key factors in the rising cost of new drug discovery and development. Nat Rev Drug Discov 3:417-29 (Pubitemid 38618124)
10. DiGiovanna JJ (2010) Fracturing support for the role of systemic retinoid therapy as a cause of bone demineralization. Arch Dermatol 146:551-3
11. Endo H, Sugioka Y, Nakagi Y et al. (2008) A novel role of the NRF2 transcription factor in the regulation of arsenite-mediated keratin 16 gene expression in human keratinocytes. Environ Health Perspect 116:873-9 (Pubitemid 351943893)
12. Erickson AM, Nevarea Z, Gipp JJ et al. (2002) Identification of a variant antioxidant response element in the promoter of the human glutamate-cysteine ligase modifier subunit gene. Revision of the ARE consensus sequence. J Biol Chem 277:30730-7 (Pubitemid 34970769)
13. Freedberg IM, Tomic-Canic M, Komine M et al. (2001) Keratins and the keratinocyte activation cycle. J Invest Dermatol 116:633-40 (Pubitemid 32467639)
14. Gough DJ, Levy DE, Johnstone RW et al. (2008) IFNgamma signaling-does it mean JAK-STAT? Cytokine Growth Factor Rev 19:383-94
15. Hattori N, Komine M, Yano S et al. (2002) Interferon-gamma, a strong suppressor of cell proliferation, induces upregulation of keratin K6, one of the inflammatory-and proliferation-associated keratins. J Invest Dermatol 119:403-10 (Pubitemid 35001950)
16. Hickerson RP, Flores MA, Leake D et al. (2011) Use of self-delivery siRNAs to inhibit gene expression in an organotypic pachyonychia congenita model. J Invest Dermatol; e-pub ahead of print 20 Jan 2011
17. Hickerson RP, Smith FJD, McLean WHI et al. (2006) SiRNA-mediated selective inhibition of mutant keratin mRNAs responsible for the skin disorder pachyonychia congenita. Ann N Y Acad Sci 1082:56-61. (Pubitemid 44955450)
18. Hickerson RP, Smith FJD, Reeves RE et al. (2008) Single-nucleotide- specific siRNA targeting in a dominant-negative skin model. J Invest Dermatol 128:594-605 (Pubitemid 351252662)
19. Kanno Y, Kozak CA, Schindler C et al. (1993) The genomic structure of the murine ICSBP gene reveals the presence of the gamma interferon-responsive element, to which an ISGF3 alpha subunit (or similar) molecule binds. Mol Cell Biol 13:3951-63 (Pubitemid 23187623)
20. Kaspar RL (2005) Challenges in developing therapies for rare diseases including pachyonychia congenita. J Investig Dermatol Symp Proc 10:62-6
21. Kaspar RL, Leachman SA, McLean WHI et al. (2011) Toward a treatment for PC: report on the 7th annual International Pachyonychia Congenita Consortium meeting. J Invest Dermatol 131:1011-14
22. Kerns ML, DePianto D, Dinkova-Kostova AT et al. (2007) Reprogramming of keratin biosynthesis by sulforaphane restores skin integrity in epidermo-lysis bullosa simplex. Proc Natl Acad Sci USA 104:14460-5 (Pubitemid 350003283)
23. Komine M, Rao LS, Freedberg IM et al. (2001) Interleukin-1 induces transcription of keratin K6 in human epidermal keratinocytes. J Invest Dermatol 116:330-8 (Pubitemid 32173739)
24. Leachman SA, Hickerson RP, Hull PR et al. (2008) Therapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenita. J Dermatol Sci 51:151-7
25. Leachman SA, Hickerson RP, Schwartz ME et al. (2010) First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther 18:442-6
26. Leachman SA, Kaspar RL, Fleckman P et al. (2005) Clinical and pathological features of pachyonychia congenita. J Investig Dermatol Symp Proc 10:3-17
27. Lee SJ, Qin H, Benveniste EN (2007) Simvastatin inhibits IFN-gamma-induced CD40 gene expression by suppressing STAT-1alpha. J Leukoc Biol 82:436-47 (Pubitemid 47230655)
28. Liao H, Sayers JM, Wilson NJ et al. (2007) A spectrum of mutations in keratins K6a, K16 and K17 causing pachyonychia congenita. J Dermatol Sci 48:199-205 (Pubitemid 350030880)
29. Ma S, Rao L, Freedberg IM et al. (1997) Transcriptional control of K5, K6, K14, and K17 keratin genes by AP-1 and NF-kappaB family members. Gene Expr 6:361-70
30. McLean WHI, Rugg EL, Lunny DP et al. (1995) Keratin 16 and keratin 17 mutations cause pachyonychia congenita. Nat Genet 9:273-8
31. McTaggart SJ (2006) Isoprenylated proteins. Cell Mol Life Sci 63:255-67 (Pubitemid 43202309)
32. Miller M (1999) New developments in the treatment of low high-density lipoprotein cholesterol. Curr Atheroscler Rep 1:24-30
33. Moll I, Bohnert E, Treib U et al. (1994) Effects of ultraviolet B radiation on cytoskeletal and adhesion molecules in human epidermis. Photodermatol Photoimmunol Photomed 10:26-32 (Pubitemid 24043497)
34. Nioi P, McMahon M, Itoh K et al. (2003) Identification of a novel Nrf2-regulated antioxidant response element (ARE) in the mouse NAD(P)H: quinone oxidoreductase 1 gene: reassessment of the ARE consensus sequence. Biochem J 374:337-48 (Pubitemid 37094093)
35. Ormerod AD, Campalani E, Goodfield MJ (2010) British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology. Br J Dermatol 162:952-63
36. Perlmann T, Rangarajan PN, Umesono K et al. (1993) Determinants for selective RAR and TR recognition of direct repeat HREs. Genes Dev 7:1411-22 (Pubitemid 23210889)
37. Radoja N, Diaz DV, Minars TJ et al. (1997) Specific organization of the negative response elements for retinoic acid and thyroid hormone receptors in keratin gene family. J Invest Dermatol 109:566-72 (Pubitemid 27433603)
38. Russell DW (1992) Cholesterol biosynthesis and metabolism. Cardiovasc Drugs Ther 6:103-10
39. Smaldone C, Brugaletta S, Pazzano V et al. (2009) Immunomodulator activity of 3-hydroxy-3-methilglutaryl-CoA inhibitors. Cardiovasc Hematol Agents Med Chem 7:279-94
40. Smith FJD, Hickerson RP, Sayers JM et al. (2008) Development of therapeutic siRNAs for pachyonychia congenita. J Invest Dermatol 128:50-8 (Pubitemid 350249391)
41. Smith FJD, Jonkman MF, van Goor H et al. (1998) A mutation in human keratin K6b produces a phenocopy of the K17 disorder pachyonychia congenita type 2. Hum Molec Genet 7:1143-8 (Pubitemid 28306880)
42. Tomic-Canic M, Freedberg IM, Blumenberg M (1996) Codominant regulation of keratin gene expression by cell surface receptors and nuclear receptors. Exp Cell Res 224:96-102 (Pubitemid 26116892)
43. Umesono K, Murakami KK, Thompson CC et al. (1991) Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors. Cell 65:1255-66 (Pubitemid 121001338)
44. Vallance P, Williams P, Dollery C (2010) The future is much closer collaboration between the pharmaceutical industry and academic medical centers. Clin Pharmacol Ther 87:525-7
45. Wakabayashi N, Itoh K, Wakabayashi J et al. (2003) Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat Genet 35:238-45 (Pubitemid 37363177)
46. Wilson NJ, Leachman SA, Hansen CD et al. (2011) A large mutational study in pachyonychia congenita. J Invest Dermatol 131:1018-24